NCT01429376已完成不适用
1) Pulmonary Function in CHF; 2) COPD Prevalence, Underdiagnosis and Overdiagnosis in CHF Patients and Its Independent Predictors; 3) Are There Signs of Systemic Inflammation in CHF With or Without COPD?
Rijnstate Hospital3 个研究点 分布在 1 个国家目标入组 234 人开始时间: 2009年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 234
- 试验地点
- 3
- 主要终点
- Pulmonary function abnormalities
研究概览
简要总结
The aim of the present study is:
- To investigate pulmonary function abnormalities (restriction, obstruction, diffusion impairment, mixed pulmonary defects) in patients with chronic heart failure (CHF) and to determine which of these pulmonary abnormalities prevail and to what extent.
- To determine the prevalence, underdiagnosis, and overdiagnosis of chronic obstructive pulmonary disease (COPD) as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF.
- To investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.
详细描述
- The impact of chronic heart failure (CHF) on pulmonary function is incompletely understood and remains controversial. It is difficult to separate the contribution of stable CHF from underlying pulmonary disease and other confounding influences, such as changes due to normal ageing, obesity, environmental exposure (mainly smoking), stability of disease, a history of coronary artery bypass grafting, and other conditions that can lead to pulmonary function abnormalities. Studies have shown that isolated or combined pulmonary function impairment, such as diffusion impairment, restriction, and to a much lesser extent airway obstruction are common in patients with CHF and can contribute to the perception of dyspnoea and exercise intolerance. Pulmonary dysfunction increases with the severity of heart failure and provides important prognostic information. Most investigators compared pulmonary function in CHF patients with normal predicted values or control subjects. However, there is only a small body of literature addressing the prevalence of different pulmonary function abnormalities in patients with CHF. In addition, these studies have included (potential) heart transplant recipients, who represent one extreme of the heart failure spectrum. The aim of the present study was to investigate the prevalence of pulmonary function abnormalities in patients with CHF and to determine which of these pulmonary abnormalities prevail and to what extent.
- Chronic obstructive pulmonary disease (COPD) frequently coexists with CHF, leading to impaired prognosis as well as diagnostic and therapeutic challenges. However, lung functional data on COPD prevalence in CHF are scarce and COPD remains widely undiagnosed or misdiagnosed. The reported prevalence rates of COPD range from 9 to 41% in European cohorts and from 11 to 52% in North American patients with heart failure. The purpose of this study was to determine the prevalence, underdiagnosis, and overdiagnosis of COPD as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF.
- There is abundant evidence of increased systemic inflammation in both CHF and COPD and it is remarkable to observe the similarities of inflammation in both conditions. These inflammatory responses may provide a mechanistic bridge between COPD and cardiac co-morbidity. However, there is no information regarding systemic inflammation when CHF and COPD coexist. It is unknown whether the combination of these two diseases leads to increased systemic inflammation in comparison to CHF alone. The aim of this study was to investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic heart failure patients with left ventricular systolic dysfunction (left ventricular ejection fraction < 40%)
- •Outpatients
- •New York Heart Association (NYHA) class I-IV
- •18 years and older
- •Informed consent
排除标准
- •Patients who do not meet the inclusion criteria
- •Patients who are not able to cooperate or undergo pulmonary function tests
- •Other diseases that can lead to obstructive lung function: asthma, cystic fibrosis
- •Malignancy with bad prognosis (survival < 6 months)
- •Hospitalisation to the pulmonary department in the past 6 weeks, in this case patients will have the pulmonary function tests ≥ 6 weeks after discharge
- •Patients who are already participating in another study within the cardiology department
- •Additional exclusion criteria for the first primary objective:
- •Disorders/diseases that can lead to pulmonary function impairment:
- •Pulmonary: lung surgery (lobectomy/pneumectomy), parenchymal neoplasms, interstitial lung disease, sarcoidosis, pneumoconioses, lung abscess, lobar pneumonia, post- infectious scarring, atelectasis, radiation fibrosis
- •Pleural: diffuse pleural thickening, mesothelioma, pleural effusion not due to heart failure, pneumothorax
- •Neuromuscular diseases: ALS, poliomyelitis, myopathy, bilateral diaphragmatic paralysis, high spinal cord lesions, myasthenia gravis
- •Abdominal: obesity (BMI > 35) (exclusion only from the restriction prevalence analysis)
- •Pericardial: major pericardial effusion
- •Large mediastinal processes
- •Collagen vascular diseases
- •Additional exclusion criteria for the third primary objective:
- •Active/recent infection
- •Febrile or inflammatory disease such as rheumatoid arthritis
- •Use of antibiotics or anti-inflammatory medication, such as etanercept, infliximab, systemic use of corticosteroids and NSAID's other than acetylsalicylic acid
- •Malignancy
- •Auto-immune disease
- •Collagenvascular disease
- •Gastro-intestinal disease (such as inflammatory bowel disease)
- •Recent operation (past 3 months)
- •Renal or liver failure
- •Thyroid disease
- •Obstructive sleep apnoea syndrome (OSAS)
- •Disorders that lead to thrombocytopenia/leukocytopenia or thrombocytosis/leukocytosis (hs-CRP analysis will take place in case these disorders do not affect hs-CRP)
结局指标
主要结局
Pulmonary function abnormalities
时间窗: 1 day
Restriction, obstruction, diffusion impairment, mixed pulmonary defects
Systemic inflammation
时间窗: 1 day
Leukocytes, platelets, high sensitivity CRP.
COPD prevalence, underdiagnosis, and overdiagnosis
时间窗: 3 months
Patients with newly diagnosed COPD repeated spirometry after 3 months of standard treatment for COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
次要结局
- Dyspnoea(3 months)
- Quality of life(3 months)
- Independent predictors of COPD(3 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Canadian Observation Trial in CF Patients Undergoing Treatment With IvacaftorCystic FibrosisNCT03390985Tanja Gonska18
撤回
不适用
A Prospective, Observational Study of COPD Patients in U.S. HospitalsChronic Obstructive Pulmonary DiseaseNCT02406534EPI-Q
已完成
不适用
Correlation Between the Pulmonary Function Parameters and the Circulatory Parameters (PSV, EDV, RI) of Retrobulbar Blood Vessels (CRA, PCA, and OA) in 48 T2DM Patients Did Not Combinate With DRDiabetes Mellitus, Type 2NCT02774733Fourth People's Hospital of Shenyang48
Unknown
3 期
Does Pulmonary Daoyin of China Give Additional Benefit Over Usual Therapy in Management of Stable Chronic Obstructive Pulmonary Disease?Pulmonary Disease, Chronic ObstructiveNCT01482000Henan University of Traditional Chinese Medicine464
已完成
不适用
A Comparison of Clinical Parameters in With and Without Abnormal Glucose Tolerance.Cystic Fibrosis-related DiabetesDiabetes MellitusCystic FibrosisNCT04503408Hacettepe University40